Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

Name: Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
Published: 2025
License: Public Domain

Merck Sharp & Dohme LLC · 2025

ClinicalTrials.gov · Datasets · License: Public Domain · 2025

Open Source ↗

renal-cell-carcinoma

renal cell carcinoma, vascular endothelial growth factor receptor-tyrosine kinase inhibitor (vegfr-tki), hypoxia-inducible factor-2α (hif-2α), interventional, phase1, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

Related documents